[Abstract] Objective: To observe the curative effect of gemcitabine combined with S-1 for treatment patients with advanced breast cancer. Methods: A total of 31 patients with advanced breast cancer were enrolled into this study. All the subjects were treated with gemcitabine 1000mg/m2, iv 0.5hour) and S-1 (80mg.m-2. d-1,oral administration after eat, two times, d1-d14). Three weeks was a cycle. Minimum 2 cycles were given. The following parameters of all the subjects were observed: clinical curative effect and adverse reactions. Results: The curative effect and adverse reactions could be evaluated in 31 patients with 2 of CR, 8 of PR，13 of SD，8 of PD，the response rate and clinical benefit rate was 32.26% and 74.19%，respectively. The most common adverse reactions were hematological and digestive toxic reaction. Conclusion: Patients with anthracycline- and (or) taxanes- resistant advanced cancer who were treated with gemcitabine combined with S-1 have a better curative effect. And their adverse reactions were also small. So it deserve its wildly used in clinical decisions.